

Around anesthesia: anesthetic aspects of electroconvulsive treatment in the light of the latest reports – review article

Patryk Rodek, Wojciech Mędrala, Jan Chrobak,
Aleksandra Barabasz-Gembczyk,
Barbara Alli-Balogun, Krzysztof Kucia

Chair and Department of Adult Psychiatry, Faculty of Medical Sciences in Katowice,
Medical University of Silesia

Summary

Electroconvulsive therapy (ECT) remains the most effective method of treating acute mental conditions in psychiatry. The progress that has been made in anesthesiology in recent years allows for the personalization and optimization of electroconvulsive therapy through purely anesthetic interventions. There are few procedures in medicine where anesthesia would have such a direct impact on the effectiveness, or even success, of a given procedure.

A key aspect of electroconvulsive therapy is a selection of the appropriate anesthetic. In Polish conditions, we have a choice of thiopental, propofol, etomidate, and ketamine – each with different, unique properties and a different impact on the generated epileptic seizure and the patient's hemodynamic safety. From the psychiatrist's perspective, etomidate and ketamine seem to be optimal, as they have no anti-epileptic effect and allow the use of lower energy values, which translates into a lower risk of cognitive dysfunction. However, their use is associated with more frequent cases of hypertension and tachycardia. Ketofol, a mixture of ketamine and propofol, helps to alleviate excessive increases in blood pressure and pulse rate through the hemostabilizing property of propofol.

Another important issue is the dose of the anesthetic used, i.e., the depth of anesthesia, which can be monitored using the bispectral index. Too deep anesthesia will result in less effectiveness of the procedure itself. The flow of the electric current requires the patient's muscles to be fully relaxed. Succinylcholine, which is a depolarizing muscle relaxant, remains the drug of choice. In the case of contraindications to its use, non-depolarizing agents, such as mivacurium or rocuronium, turn out to be useful, although the duration of the procedure is definitely longer. Sugammadex allows for full abolition of rocuronium-induced relaxation, but it remains a drug that is usually unaffordable.

Key words: anesthesia, electroconvulsive therapy

Introduction

Agents that modulate the autonomic response

Immediately after the electrical impulse is delivered, extreme stimulation of the vagus nerve occurs, which leads to parasympatholysis, bradycardia, transient hypotension and electrical interruption, which lasts more than 5 seconds in approximately 5% of patients [1–3]. It is believed that asystole longer than 10 seconds may pose a threat to the patient. A greater risk of prolonged electrical pause has been associated with the use of beta-blockers, high doses of suxamethonium, the use of thiopental as an anesthetic, bilateral electrode placement, and repeated subthreshold stimulation [4]. Prolonged asystole, which may pose a threat to the patient, can be prevented by intravenous premedication, usually immediately before the procedure itself, with the use of anticholinergics, mainly atropine (usually in doses of 300 to 600 µg) [5]. Glycopyrronium bromide turns out to be a substance with a more favorable action profile in this indication, as it does not cross the blood-brain barrier, giving a lower risk of cognitive disorders, but in Poland it is available only in inhalation form as a drug used in lung diseases [6, 7]. Atropine, in addition to its effect on heart rate, reduces salivation after ECT, which may be particularly useful in patients treated with clozapine to minimize the risk of aspiration pneumonia [8].

During the clonic phase of an epileptic seizure, the levels of catecholamines in the adrenal medulla increase up to 15 times, which leads to tachycardia and an increase in blood pressure [9]. The substance used to lower blood pressure during ECT is urapidil (usually an i.v. bolus of 25mg), which is a fast-acting postsynaptic α_1 -adrenoceptor antagonist, although so far we have only one study comparing its effectiveness with other agents more frequently used in this indication, such as esmolol (usually 1 mg/kg) or labetalol (usually 0.2 mg/kg) [10, 11].

Choice of anesthetic agent

The choice of an anesthetic is one of the most important decisions during ECT procedures and can often determine the effects of treatment. Wagner et al. [12] summed up the features that an ideal anesthetic should have: quick and smooth induction of anesthesia, painless injection, no or minimal anti-epileptic properties, short duration of action, and a synergistic or additive effect to ECT alone. In Poland, the anesthetics that are used during ECT include thiopental, propofol, etomidate, and ketamine, which differ greatly in their properties [13].

By influencing GABA-ergic transmission, both thiopental and propofol significantly increase the seizure threshold [14]. This is associated with a greater number of abortive seizures, a shorter duration of epileptic activity and, as a result, the need to use higher electrical charges. The effect is more expressed with the use of propofol due to the additional blocking of sodium channels [15]. Ketamine and etomidate, on the other hand, have no or minimal antiepileptic effect [16, 17].

Hoyer et al. [18] compared the agents used to induce anesthesia in terms of their impact on the quality of the epileptic seizure and the profile of side effects. In the group

of patients receiving ketamine and etomidate, the effectiveness of epileptic seizures was definitely higher, it turned out to be lower with thiopental and the lowest with propofol, in the case of which almost 14% of all seizures were classified as probably ineffective. These reports coincide with many others proving the advantage of ketamine or etomidate over anesthetics with antiepileptic properties [19]. On the other hand, propofol and thiopental provide the best hemodynamic stabilization, preventing post-ictal increases in blood pressure and tachycardia [20, 21].

The use of inhalation anesthetics for electroconvulsive therapy remains debatable. In a recent comparison of sevoflurane with thiopental, it was shown that its use was associated with a higher percentage of unsuccessful procedures, more frequent need for restimulation, higher increases in maximum heart rate, and a greater number of necessary procedures [22, 23].

Specific properties of ketamine

Ketamine is a non-selective NMDA receptor antagonist with intrinsic antidepressant activity, although the mechanism of this action remains unclear [24]. In psychiatry, it was not used for many years due to its potential to cause dissociative symptoms, including visual and auditory hallucinations [25]. However, this is a dose-dependent effect, ketamine shows psychomimetic properties at plasma concentrations from 100 ng/mL to 250 ng/mL, while its concentrations during general anesthesia exceed 2,600 ng/mL [26]. So far, no worsening of symptoms in patients with schizophrenia or schizoaffective disorders has been reported [27].

What distinguishes ketamine from other agents is its effect on the cardiovascular system, it inhibits the respiratory center to a much lesser extent, only slightly reduces laryngeal reflexes, increases blood pressure and heart rate [28]. In addition, it strongly dilates the bronchi (similarly to propofol), which may prove beneficial in people with asthma or chronic obstructive pulmonary disease, while etomidate and thiopental have the opposite effect due to a greater or lesser effect on the release of histamine [29].

Despite theoretical premises and preliminary reports on the additive effect of ketamine on ECT, current research brings ambiguous results. A recent double-blind RCT under the acronym KANECT did not show any advantage of ketamine over propofol in terms of the effectiveness of ECT [30]. Also, the addition of small subanesthetic doses of ketamine to anesthesia with another anesthetic did not increase the effectiveness of ECT, was not associated with a faster resolution of symptoms, and did not significantly affect the cognitive functions of patients [31, 32].

The combination of ketamine and propofol in one mixture is common in anesthesiology under the name of “ketofol” and is particularly used during ECT procedures [33–35]. Ketamine provides a lower seizure threshold, which results in the possibility of using smaller electric charges, and this translates into a reduced risk of cognitive dysfunction [36]. Propofol, on the other hand, limits post-ictal increases in BP and HR, which also reduces the risk of cognitive dysfunction and the risk of postoperative agitation [37]. In anesthesiology, ketofol is usually used as a 1:3 mixture of ketamine to propofol [38]. Sartorius et al. [39], in a retrospective evaluation of various mixtures

of ketofol, showed that from the point of view of ECT, the most favorable ratio of ketamine to propofol is 3:1 or 1.5:1 with S-ketamine.

Specific uses of anesthetic agents

Although the risk of a prolonged epileptic seizure exceeding 120 seconds (or 180 seconds according to other authors) is not high and amounts to about 0.4%, it may be associated with severe cognitive impairment and prolonged awakening [19, 20]. A single bolus of an anesthetic with anticonvulsant properties, such as propofol (usually 30–50 mg) or thiopental (usually 50–100 mg) or benzodiazepines (e.g., 1 mg of clonazepam or 10 mg of diazepam) is most often used to stop an epileptic seizure [40–42]. So far, 13 cases of generalized non-convulsive and 3 cases of ECT-induced seizures have been described [43]. In cases of prolonged epileptic seizures resistant to pharmacological actions, epileptic activity can be interrupted using electrical stimulation with a charge at least twice as high as applied [44].

Dexmedetomidine, a selective central α_2 receptor agonist with a strong sedative and analgesic effect, is a substance that is particularly used during ECT procedures [45]. A significant complication of ECT procedures is post-ictal agitation (PIA), which may occur in up to 12% of all patients and usually requires additional interventions [46]. Premedication with dexmedetomidine prior to ketamine anesthesia reduces the risk of developing PIA by almost half [47]. Moreover, it alleviates the hemodynamic response during an epileptic seizure, significantly reduces the maximum systolic and diastolic blood pressure and heart rate, while not affecting the time to awakening or prolonging the electrical interval after the flow of an electrical impulse [48].

In situations where there are contraindications to replacing the anticonvulsant anesthetic with etomidate or ketamine, and with a high seizure threshold, it may be beneficial to add short-acting opioids, taking advantage of their opioid sparing effect, which allows to reduce the dose of propofol or thiopental necessary for induction [19, 20]. Adding, e.g., remifentanyl (1 $\mu\text{g/kg}$) to propofol in a recent meta-analysis was associated with the possibility of using up to half the doses of propofol, and thus resulted in an increase in the duration of seizure activity [49, 50]. Moreover, it reduced the maximum values to which the systolic blood pressure increased [51]. Kessler et al. [52], however, draws attention to the need for considerable caution in the routine addition of remifentanyl to barbiturate anesthesia, as it does not affect the long-term remission and recurrence rates, and is associated with a higher risk of side effects, such as nausea, dizziness or headaches. According to the latest network meta-analysis, the use of remifentanyl seems to be the best option in the prevention of myoclonus induced by etomidate, which may be of particular importance in patients with a high baseline concentration of potassium with the simultaneous use of succinylcholine, as both myoclonus and succinylcholine cause a strong shift of potassium ions outside the muscle cell [53].

Depth of anesthesia

Another aspect of anesthesia, apart from the type of anesthetic, is its depth itself, depending on the dose of the anesthetic used. Too deep anesthesia is associated with more difficult induction of an epileptic seizure, its worse morphology and duration [54, 55]. The single numerical parameter indicating the depth of anesthesia is the bispectral index (BIS), which transforms many EEG parameters into a numerical value from 0, which indicates the lack of electrical brain activity, to 100, i.e., full consciousness [56]. Typically, during other procedures requiring general anesthesia, the BIS value is between 40 and 60, however, in the case of ECT, it has been retrospectively demonstrated in a relatively large group of patients that the higher the BIS, i.e., the shallower the anesthesia, the better the seizure response [57]. Kranaster et al. [57] showed that with BIS 65, i.e., on the border of light anesthesia and deep sedation, the energy load necessary to induce an adequate epileptic seizure was almost three times lower than with BIS 60. It should be remembered that in the case of ketamine anesthesia, BIS monitoring is pointless due to the fact that ketamine induces dissociated anesthesia [58].

Muscle relaxants

The flow of electric charge is necessarily associated with the need to fully relax the patient's muscles. Although the type of myorelaxant used does not affect the effectiveness of the procedure as much as in the case of an anesthetic, one should remember about some specificity of ECT procedures. The agent of choice remains succinylcholine, which provides quick and short-term relaxation with a good safety profile. However, its depolarizing effect on the muscle plate is associated with certain limitations, e.g., it should not be used in the case of hyperkalemia, extensive burns, spinal, peripheral nerve and muscle injuries [59]. It is also a known risk factor for malignant hyperthermia [60]. Moreover, there are reports of prolonged apnea in patients with butyrylcholinesterase deficiency [61]. In all these situations, non-depolarizing agents, such as mivacurium or atracurium, turn out to be effective, although then the time of the procedure itself is significantly longer.

It was shown that the use of cisatracurium was associated with a lower increase in potassium concentration, longer duration of the epileptic seizure, faster return of spontaneous breathing, and lower postoperative tachycardia compared to succinylcholine [62]. A retrospective analysis of 500 cases indicates exceptional individual variability in susceptibility to succinylcholine [63]. In order to achieve adequate relaxation, it was necessary to use doses ranging from 0.29 mg/kg to even 2.1 mg/kg. The standard dose of 0.9 mg/kg body weight should therefore be used during the first treatment, and then individually adjusted to the patient during subsequent ECTs. Asztalos et al. [64] showed that extending the time from succinylcholine administration to charge flow by 30 seconds (up to 120 seconds) was associated with fewer necessary restimulations.

An interesting option seems to be to shorten the duration of the relaxation caused by rocuronium by using sugammadex, which is a modified gamma cyclodextrin molecule,

which ensures complete abolition of the relaxation caused by non-depolarizing drugs of steroid structure by their encapsulation into water-soluble guest-host complexes [65]. So far, the effective use of the rocuronium-sugammadex combination during ECT procedures in patients with Brugada syndrome, in cases of neuroleptic malignant syndrome, during hemodialysis and in pseudocholinesterase deficiency has been described [66–68]. In addition, the abolition of neuromuscular blockade with sugammadex was associated with a lower risk of headache and muscle pain after the procedure, as well as shorter reorientation time [69, 70]. In most countries, including Poland, due to the high costs associated with the use of sugammadex, its use for ECT procedures is significantly limited. A more available alternative to rocuronium and sugammadex may be the reversal of mivacurium-induced muscle block with intravenous administration of neostigmine at a dose of 0.5–2 mg. [71].

Recapitulation

Although ECT procedures are currently performed in accordance with the highest standards and are characterized by a high safety profile, the progress made in anesthesiology makes it possible to optimize their effectiveness and reduce potential side effects. Individual and personalized adaptation of the anesthesia protocol, choice of anesthetic and muscle relaxant, the depth of anesthesia itself, and finally the use of additional corrective drugs make ECT a much more acceptable form of treatment for severe mental disorders both for patients, their families and other physicians specialties.

References

1. Coughlin JM, Rodenbach K, Lee PH, Hayat MJ, Griffin MM, Mirski MA et al. *Asystole in ultrabrief pulse electroconvulsive therapy*. J. ECT 2012; 28(3): 165–169. Doi: 10.1097/YCT.0B013E31825003F9.
2. Roche NC, Raynaud L, Bompaire F, Lucas JJ, Auxéméry Y. *Asystolie perstimulus résultant d'une hypertonie parasympathique au cours des électroconvulsivothérapies: cas clinique, brève revue de la littérature et discussion*. Encephale 2016; 42(1): 59–66. Doi: 10.1016/j.encep.2015.06.004.
3. Mizen L, Morton C, Scott A. *The cardiovascular safety of the empirical measurement of the seizure threshold in electroconvulsive therapy*. BJPsych. Bull. 2015; 39(1): 14–18. Doi: 10.1192/PB.BP.112.038695.
4. Tang WK, Ungvari GS. *Asystole during electroconvulsive therapy: A case report*. Aust. N. Z. J. Psychiatry 2001; 35(3): 382–385. Doi: 10.1046/J.1440-1614.2001.00892.X.
5. Jadhav T, Sriganesh K, Thirthalli J, Reddy KRM, Venkataramaiah S, Philip M et al. *Effect of atropine premedication on cardiac autonomic function during electroconvulsive therapy*. J. ECT 2017; 33(3): 176–180. Doi: 10.1097/YCT.0000000000000417.
6. Rasmussen P, Andersson JE, Koch P, Secher NH, Quistorff B. *Glycopyrrolate prevents extreme bradycardia and cerebral deoxygenation during electroconvulsive therapy*. J. ECT 2007; 23(3): 147–152. Doi: 10.1097/YCT.0B013E318033FFD8.

7. Grillet PE, Le Souder C, Rohou J, Cazorla O, Charriot J, Bourdin A. *Glycopyrrolate and formoterol fumarate for the treatment of COPD*. Expert Rev. Respir. Med. 2021; 15(1): 13–25. Doi: 10.1080/17476348.2020.1807946.
8. Mubaslat O, Lambert T. *The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: A multicentre, randomised placebo-controlled trial*. Psychopharmacology (Berl.) 2020; 237(10): 2905–2915. Doi: 10.1007/S00213-020-05627-4.
9. Weinger MB, Partridge BL, Hauger R, Mirow A. *Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: I. Effectiveness of pretreatment regimens on hemodynamics*. Anesth. Analg. 1991; 73(5): 556–562.
10. Blanch J, Martínez-Pallí G, Navinés R, Arcega JM, Imaz ML, Santos P et al. *Comparative hemodynamic effects of urapidil and labetalol after electroconvulsive therapy*. J. ECT 2001; 17(4): 275–279. Doi: 10.1097/00124509-200112000-00007.
11. Parikh D, Garg S, Dalvi N, Surana P, Sannakki D, Tendolkar B. *Outcome of four pretreatment regimes on hemodynamics during electroconvulsive therapy: A double-blind randomized controlled crossover trial*. Ann. Card. Anaesth. 2017; 20(1): 93–99. Doi: 10.4103/0971-9784.197844.
12. Wagner KJ, Möllenberg O, Rentrop M, Werner C, Kochs EF. *Guide to anaesthetic selection for electroconvulsive therapy*. CNS Drugs 2005; 19(9): 745–758. Doi: 10.2165/00023210-200519090-00002.
13. Wojdacz R, Antosik-Wójcińska A, Świącicki Ł. *Complications of general anaesthesia in electroconvulsive therapy*. Pharmacother. Psychiatry Neurol. 2022; 37(3): 245–257. Doi: 10.5114/FPN.2021.115555.
14. Modica PA, Tempelhoff R, White PF. *Pro – and anticonvulsant effects of anesthetics (Part I)*. Anesth. Analg. 1990; 70(3): 303–315. Doi: 10.1213/00000539-199003000-00013.
15. Trapani G, Altomare C, Sanna E, Biggio G, Liso G. *Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery*. Curr. Med. Chem. 2012; 7(2): 249–271. Doi: 10.2174/0929867003375335.
16. Kucia K, Merk W. *The use of ketamine in electroconvulsive therapy*. Psychiatr. Pol. 2015; 49(6): 1255–1263. Doi: 10.12740/PP/31748.
17. Zavorotnyy M, Kluge I, Ahrens K, Wohltmann T, Köhnlein B, Dietsche P et al. *S-ketamine compared to etomidate during electroconvulsive therapy in major depression*. Eur. Arch. Psychiatry Clin. Neurosci. 2017; 267(8): 803–813. Doi: 10.1007/S00406-017-0800-3.
18. Hoyer C, Kranaster L, Janke C, Sartorius A. *Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: A retrospective study*. Eur. Arch. Psychiatry Clin. Neurosci. 2014; 264(3): 255–261. Doi: 10.1007/s00406-013-0420-5.
19. Geretsegger C, Nickel M, Judendorfer B, Rochowanski E, Novak E, Aichhorn W. *Propofol and methohexital as anesthetic agents for electroconvulsive therapy: A randomized, double-blind comparison of electroconvulsive therapy seizure quality, therapeutic efficacy, and cognitive performance*. J. ECT 2007; 23(4): 239–243. Doi: 10.1097/0B013E31814DA971.
20. Mehta D, Palta S, Gupta N, Saroa R. *Comparison of effect of etomidate with propofol on hemodynamics during modified electroconvulsive therapy*. J. Anaesthesiol. Clin. Pharmacol. 2022; 38(1): 104. Doi: 10.4103/JOACP.JOACP_185_20.
21. Wojdacz R, Swiecicki Ł, Antosik-Wójcinska A. *Comparison of the effect of intravenous anesthetics used for anesthesia during electroconvulsive therapy on the hemodynamic safety and the course of ECT*. Psychiatr. Pol. 2017; 51(6): 1039–1058. Doi: 10.12740/PP/75635.

22. Yatomi T, Uchida T, Takamiya A, Wada M, Kudo S, Nakajima K et al. *Impact of sevoflurane and thiopental used over the course of electroconvulsive therapy: Propensity score matching analysis*. *Front. Hum. Neurosci.* 2022; 16: 933622. Doi: 10.3389/FNHUM.2022.933622.
23. Aoki N, Suwa T, Kawashima H, Tajika A, Sunada N, Shimizu T et al. *Sevoflurane in electroconvulsive therapy: A systematic review and meta-analysis of randomised trials*. *J. Psychiatr. Res.* 2021; 141: 16–25. Doi: 10.1016/J.JPSYCHIRES.2021.06.030.
24. Gálvez V, McGuirk L, Loo CK. *The use of ketamine in ECT anaesthesia: A systematic review and critical commentary on efficacy, cognitive, safety and seizure outcomes*. *World J. Biol. Psychiatry* 2017; 18(6): 424–444. Doi: 10.1080/15622975.2016.1252464.
25. Hasselmann HWW. *Ketamine as antidepressant? Current state and future perspectives*. *Curr. Neuropharmacol.* 2014; 12(1): 57. Doi: 10.2174/1570159X113119990043.
26. Rozet I. *Ketamine in depression and electroconvulsive therapy*. *Curr. Opin. Anaesthesiol.* 2021; 34(5): 556–562. Doi: 10.1097/ACO.0000000000001039.
27. Kranaster L, Hoyer C, Janke C, Sartorius A. *Preliminary evaluation of clinical outcome and safety of ketamine as an anesthetic for electroconvulsive therapy in schizophrenia*. *World J. Biol. Psychiatry* 2014; 15(3): 242–250. Doi: 10.3109/15622975.2011.647833.
28. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P et al. *Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms*. *Pharmacol. Rev.* 2018; 70(3): 621. Doi: 10.1124/PR.117.015198.
29. Burburan SM, Xisto DG, Rocco PRM. *Anaesthetic management in asthma*. *Minerva Anesthesiol.* 2007; 73(6): 357–365.
30. Fernie G, Currie J, Perrin JS, Stewart CA, Anderson V, Bennett DM et al. *Ketamine as the anaesthetic for electroconvulsive therapy: The KANECT randomised controlled trial*. *Br. J. Psychiatry* 2017; 210(6): 422–428. Doi: 10.1192/bjp.bp.116.189134.
31. Anderson IM, Blamire A, Branton T, Clark R, Downey D, Dunn G et al.; Ketamine-ECT Study team. *Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): A multicentre, double-blind, randomised, parallel-group, superiority trial*. *Lancet Psychiatry* 2017; 4(5): 365–377. Doi: 10.1016/S2215-0366(17)30077-9.
32. Woolsey AJ, Nanji JA, Moreau C, Sivapalan S, Bourque SL, Ceccherini-Nelli A et al. *Low-dose ketamine does not improve the speed of recovery from depression in electroconvulsive therapy: A randomized controlled trial*. *Rev. Bras. Psiquiatr.* 2022; 44(1): 6–14. Doi: 10.1590/1516-4446-2020-1705.
33. Gurel SC, Ozden HC, Karahan S, Ayhan Y. *The superiority of ketofol and etomidate against propofol or thiopental anesthesia for ECT*. *Asian J. Psychiatr.* 202; 72: 103090. Doi: 10.1016/J.AJP.2022.103090.
34. Gaddam NR, Kelkar Sasturkar VP, Kulkarni SJ, Joshi PS, Bhale PV. *A comparative study of propofol, thiopentone sodium, and ketofol as induction agents for electroconvulsive therapy*. *J. Anaesthesiol. Clin. Pharmacol.* 2021; 37(4): 554–560. Doi: 10.4103/JOACP.JOACP_423_19.
35. Zheng W, He M, Gu LM, Lao GH, Wang DF, Mai JX et al. *Early improvement as a predictor of final remission in patients with treatment-resistant depression receiving electroconvulsive therapy with ketofol anesthesia*. *J. Affect. Disord.* 2022; 310: 223–227. Doi: 10.1016/J.JAD.2022.05.027.
36. Sharma RK, Kulkarni G, Kumar CN, Arumugham SS, Sudhir V, Mehta UM et al. *Antidepressant effects of ketamine and ECT: A pilot comparison*. *J. Affect. Disord.* 2020; 276: 260–266. Doi: 10.1016/J.JAD.2020.07.066.

37. McGirr A, Berlim MT, Bond DJ, Neufeld NH, Chan PY, Yatham LN et al. *A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability*. J. Psychiatr. Res. 2015; 62: 23–30. Doi: 10.1016/J.JPSYCHIRES.2015.01.003.
38. Coulter FLS, Hannam JA, Anderson BJ. *Ketofol dosing simulations for procedural sedation*. Pediatr. Emerg. Care 2014; 30(9): 621–630. Doi: 10.1097/PEC.0000000000000222.
39. Sartorius A, Beuschlein J, Remennik D, Pfeifer AM, Karl S, Bumb JM et al. *Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality*. Eur. Arch. Psychiatry Clin. Neurosci. 2021; 271(3): 457–463. Doi: 10.1007/s00406-020-01170-7.
40. Walter G, Rey JM. *Has the practice and outcome of ect in adolescents changed? Findings from a whole-population study*. J. ECT 2003; 19(2): 84–87. Doi: 10.1097/00124509-200306000-00005.
41. Tiller JW, Lyndon RW, editors. *Electroconvulsive therapy: An Australasian guide*. Melbourne: Australian Postgraduate Medicine; 2003. https://books.google.com/books/about/Electroconvulsive_Therapy.html?hl=pl&id=hF_WrAAAACAAJ (retrieved: 4.08.2022).
42. Royal College of Psychiatrists, Scott AIF. *The ECT handbook*, 2nd ed. The Third Report of the Royal College of Psychiatrists' Special Committee on ECT (Council Report CR128); 2005.
43. Wieben E, Kjeldsen MJ, Sørensen CH. *Convulsive status epilepticus induced by electroconvulsive therapy in a patient with major depression*. Case Rep. Psychiatry 2022; 2022: 8545991. Doi: 10.1155/2022/8545991.
44. Krystal AD, Coffey CE. *Neuropsychiatric considerations in the use of electroconvulsive therapy*. J. Neuropsychiatry Clin. Neurosci. 1997; 9(2): 283–292. Doi: 10.1176/JNP.9.2.283.
45. Keating GM. *Dexmedetomidine: A review of its use for sedation in the intensive care setting*. Drugs 2015; 75(10): 1119–1130. Doi: 10.1007/S40265-015-0419-5.
46. Allen ND, Allison CL, Golebiowski R, Janowski JPB, LeMahieu AM, Geske JR et al. *Factors associated with postictal agitation after electroconvulsive therapy*. J. ECT 2022; 38(1): 60–61. Doi: 10.1097/YCT.0000000000000807.
47. Aksay SS, Bumb JM, Remennik D, Thiel M, Kranaster L, Sartorius A et al. *Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia*. Neuropsychiatr. Dis. Treat. 2017; 13: 1389–1394. Doi: 10.2147/NDT.S134751.
48. Subsoontorn P, Lekprasert V, Waleeprakhon P, Ittasakul P, Laopuangsak A, Limpoon S. *Premedication with dexmedetomidine for prevention of hyperdynamic response after electroconvulsive therapy: A cross-over, randomized controlled trial*. BMC Psychiatry 2021; 21(1): 408. Doi: 10.1186/S12888-021-03406-9.
49. İkiz C, Günenç F, İyilikçi L, Özbilgin Ş, Ellidokuz H, Cimilli C et al. *Effects of propofol and propofol-remifentanyl combinations on haemodynamics, seizure duration and recovery during electroconvulsive therapy*. Turk. J. Anaesthesiol. Reanim. 2021; 49(1): 44–51. Doi: 10.5152/TJAR.2020.157.
50. Gálvez V, Tor PC, Bassa A, Hadzi-Pavlovic D, MacPherson R, Marroquin-Harris M et al. *Does remifentanyl improve ECT seizure quality?* Eur. Arch. Psychiatry Clin. Neurosci. 2016; 266(8): 719–724. Doi: 10.1007/s00406-016-0690-9.
51. Takekita Y, Suwa T, Sunada N, Kawashima H, Fabbri C, Kato M et al. *Remifentanyl in electroconvulsive therapy: A systematic review and meta-analysis of randomized controlled trials*. Eur. Arch. Psychiatry Clin. Neurosci. 2016; 266(8): 703–717. Doi: 10.1007/s00406-016-0670-0.

52. Kessler U, Bjorke-Bertheussen J, Søreide E, Hunderi PA, Bache-Mathiesen L, Oedegaard KJ et al. *Remifentanyl as an adjunct to anaesthesia for electroconvulsive therapy fails to confer long-term benefits*. Br. J. Anaesth. 2018; 121(6): 1282–1289. Doi: 10.1016/J.BJA.2018.07.011.
53. Zhang KD, Wang LY, Zhang DX, Zhang ZH, Wang HL. *Comparison of the effectiveness of various drug interventions to prevent etomidate-induced myoclonus: A Bayesian network metaanalysis*. Front. Med. (Lausanne) 2022; 9: 799156. Doi: 10.3389/FMED.2022.799156/FULL.
54. Sartorius A, Muñoz-Canales EM, Krumm B, Krier A, Andres FJ, Bender HJ et al. *ECT anesthesia: The lighter the better?* Pharmacopsychiatry 2006; 39(6): 201–204. Doi: 10.1055/S-2006-950395/ID/28.
55. Gasteiger L, Heil M, Hörner E, Andexer J, Kemmler G, Hausmann A et al. *Relationship between anesthesia depth and quality of seizures in patients undergoing electroconvulsive therapy: A prospective observational study*. J. ECT 2022; 38(1): 62–67. Doi: 10.1097/YCT.0000000000000792.
56. Mathur S, Patel J, Goldstein S, Jain A. *Bispectral index*. Underst. Anesth. Equip. Proced. A Pract. Approach 2022; 304–304. Doi: 10.5005/jp/books/12503_30.
57. Kranaster L, Hoyer C, Janke C, Sartorius A. *Bispectral index monitoring and seizure quality optimization in electroconvulsive therapy*. Pharmacopsychiatry 2013; 46(4): 147–150. Doi: 10.1055/S-0032-1331748/ID/R2012-08-0186-0029.
58. Hans P, Dewandre PY, Brichant JF, Bonhomme V. *Comparative effects of ketamine on Bispectral Index and spectral entropy of the electroencephalogram under sevoflurane anaesthesia*. Br. J. Anaesth. 2005; 94(3): 336–340. Doi: 10.1093/BJA/AEI047.
59. Vachon CA, Warner DO, Bacon DR. *Succinylcholine and the Open Globe* Tracing the Teaching. Anesthesiology 2003; 99(1): 220–223. Doi: 10.1097/00000542-200307000-00033.
60. Blais A. *Succinylcholine, malignant hyperthermia and rhabdomyolysis*. C. Can. Med. Assoc. J. 2022; 194(25): E878. Doi: 10.1503/CMAJ.146480-L.
61. Al-Emam A. *Butyryl-cholinesterase deficiency: A case report of delayed recovery after general anaesthesia*. Toxicol. Reports 2021; 8: 1226–1228. Doi: 10.1016/J.TOXREP.2021.06.016.
62. Nazemroaya B, Ghosouri A, Honarmand A, Hashemi ST. *Comparison of hemodynamic changes and serum potassium levels in the use of succinylcholine and cisatracurium in electroconvulsive therapy*. J. Res. Med. Sci. 2021; 26(1): 106. Doi: 10.4103/JRMS.JRMS_951_19.
63. Bryson EO, Kellner CH, Li EH, Aloysi AS, Majeske M. *Extreme variability in succinylcholine dose for muscle relaxation in electroconvulsive therapy*. Australas. Psychiatry 2018; 26(4): 391–393. Doi: 10.1177/1039856218761301.
64. Asztalos M, Matzen P, Licht RW, Hesselund KB, Sartorius A, Nielsen RE. *Delaying initiation of electroconvulsive treatment after administration of the anaesthetic agent and muscle relaxant reduces the necessity of re-stimulation*. Nord. J. Psychiatry 2018; 72(5): 341–346. Doi: 10.1080/08039488.2018.1459833.
65. Ezri T, Boaz M, Sherman A, Armaly M, Berlovitz Y. *Sugammadex: An update*. J. Crit. Care Med. (Targu Mures) 2016; 2(1): 16–21. Doi: 10.1515/JCCM-2016-0005.
66. Kurita S, Moriwaki K, Shiroyama K, Sanuki M, Toyota Y, Takebayashi M. *Rocuroniumsugammadex use for electroconvulsive therapy in a hemodialysis patient: A case report*. JA Clin. Rep. 2016; 2(1): 28. Doi: 10.1186/S40981-016-0055-4.
67. Konishi J, Suzuki T, Kondo Y, Baba M, Ogawa S. *Rocuronium and sugammadex used effectively for electroconvulsive therapy in a patient with Brugada syndrome*. J. ECT 2012; 28(2): e21–e22. Doi: 10.1097/YCT.0B013E31824B74F5.

68. Casas Reza P, Gestal Vázquez M, Outeiro Rosato Á, López Álvarez S, Diéguez García P. *Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report*. Rev. Esp. Anesthesiol. Reanim. 2017; 64(2): 105–107. Doi: 10.1016/J.RENDAR.2016.04.006.
69. Saricicek V, Sahin L, Bulbul F, Ucar S, Sahin M. *Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?* J. ECT 2014; 30(1): 30–34. Doi: 10.1097/YCT.0B013E3182972BD2.
70. Kadoi Y, Hoshi H, Nishida A, Saito S. *Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy*. J. Anesth. 2011; 25(6): 855–859. Doi: 10.1007/S00540-011-1236-Y.
71. González A, Benavides J, Lema G. *Anesthesia and electroconvulsive therapy: When succinylcholine is contraindicated*. J. ECT 2013; 29(1): 75–76. Doi: 10.1097/YCT.0B013E3182673228.

Address: Patryk Rodek
Medical University of Silesia
Faculty of Medical Sciences in Katowice
Chair and Department of Adult Psychiatry
e-mail: patrykrodek2208@gmail.com